Network pharmacology to unveil the mechanism of Moluodan in the treatment of chronic atrophic gastritis

Background: Moluodan (MLD) is a traditional Chinese patent medicine for the treatment of chronic atrophic gastritis (CAG). However, the mechanism of action (MoA) of MLD for treating CAG still remain unclear.& nbsp;Purpose: Elucidate the MoA of MLD for treating CAG based on network pharmacology.& nbsp;Study design: Integrate computational prediction and experimental validation based on network pharmacology.& nbsp;Methods: Computationally, compounds of MLD were scanned by LC-MS/MS and the target profiles of compounds were identified based on network-based target prediction method. Compounds in MLD were compared with western drugs used for gastritis by hierarchical clustering of target profile. Key biological functional modules of MLD were analyzed, and herb-biological functional module network was constructed to elucidate combinatorial rules of MLD herbs for CAG. Experimentally, MLD's effect on different biological functional modules were validated from both phenotypic level and molecular level in 1-Methyl-3-nitro-1-nitrosoguanidine (MNNG)-induced GES-1 cells.& nbsp;Results: Computational results show that the target profiles of compounds in MLD can cover most of the bio-molecules reported in literature. The MoA of MLD can cover most types of MoA of western drugs for CAG. The treatment of CAG by MLD involved the regulation of various biological functional modules, e.g., inflammation/immune, cell proliferation, cell apoptosis, cell differentiation, digestion and metabolism. Experimental results show that MLD can inhibit cell proliferation, promote cell apoptosis and differentiation, reduce the inflammation level and promote lipid droplet accumulation in MNNG-induced GES-1 cells.& nbsp;Conclusion: The network pharmacology framework integrating computational prediction and experimental validation provides a novel way for exploring the MoA of MLD.

Automated summary

The mechanism of action (MoA) of traditional Chinese patent medicine Moluodan (MLD) for treating chronic atrophic gastritis (CAG) was elucidated using a network pharmacology approach. Computational analysis showed that the target profiles of MLD compounds covered most bio-molecules reported in literature and the MoA of MLD covered most types of MoA of western drugs for CAG. MLD treatment involved the regulation of various biological functional modules, and experimental validation confirmed its inhibitory effects on cell proliferation, promotion of cell apoptosis and differentiation, reduction of inflammation, and promotion of lipid droplet accumulation in MNNG-induced GES-1 cells.